Search results
Results From The WOW.Com Content Network
In 2009, Novartis reached an agreement to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the group's limited presence in this fast-growing market segment.
Ranjit Shahani, vice-chairman and managing director of Novartis India Ltd is quoted as saying "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options." [62] He also said that companies like Novartis would invest less money in research in India as a result of the ruling. [46]
Troikaa Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Ahmedabad city of Gujarat, India. [1] It is a public unlisted company and is classified as company limited by shares. [2] [3]
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
Novartis CEO Vas Narasimhan has been vocal about the pressure the drug industry is facing both in the U.S. and in Europe, but he argues the Inflation Reduction Act and Europe's proposed patent ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Ciba was a chemical company based in and near Basel, Switzerland. "Ciba" stood for "Chemische Industrie Basel" (Chemical Industries Basel) and was formed when the non-pharmaceuticals elements of Novartis were spun out in 1997, [1] following the merger in the previous year of Ciba-Geigy and Sandoz that created Novartis.
Strategic collaborations are a driving force behind the market’s rapid growth. Pharmaceutical giants such as Novartis and Bristol-Myers Squibb have entered into key partnerships with biotech firms to expand their cell therapy portfolios. These alliances are helping to accelerate the development and commercialization of novel therapies.